Literature DB >> 30507062

Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-α.

Alexis Mathian1, Suzanne Mouries-Martin2, Karim Dorgham3, Hervé Devilliers4, Laura Barnabei5, Elyès Ben Salah3, Fleur Cohen-Aubart1, Laura Garrido Castillo3, Julien Haroche1, Miguel Hie6, Marc Pineton de Chambrun6, Makoto Miyara3, Delphine Sterlin3, Micheline Pha6, Du Lê Thi Huong6, Frédéric Rieux-Laucat5, Flore Rozenberg7, Guy Gorochov3, Zahir Amoura1.   

Abstract

OBJECTIVE: No simple or standardized assay is available to quantify interferon-α (IFNα) in routine clinical practice. Single-molecule array (Simoa) digital enzyme-linked immunosorbent assay (ELISA) technology enables direct IFNα quantification at attomolar (femtogram per milliliter [fg/ml]) concentrations. This study was undertaken to assess IFNα digital ELISA diagnostic performances to monitor systemic lupus erythematosus (SLE) activity.
METHODS: IFNα concentrations in serum samples from 150 consecutive SLE patients in a cross-sectional study were determined with digital ELISA and a functional biologic activity assay (bioassay). According to their Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) flare composite scores, patients were divided into groups with inactive SLE (SLEDAI score of <4 or clinical SLEDAI score of 0) or active SLE (SLEDAI score of ≥4 or clinical SLEDAI score of >0), and into groups with no flare or mild/moderate flare or severe flare.
RESULTS: Based on serum samples from healthy blood donors, the abnormal serum IFNα level threshold value was 136 fg/ml. Next, using receiver operating characteristic curves for an SLE patient series that was widely heterogeneous in terms of disease activity and organ involvement, the threshold IFNα value associated with active disease was determined to be 266 fg/ml. The digital ELISA-assessed serum IFNα level was a better biomarker of disease activity than the Farr assay because its specificity, likelihood ratio for positive results, and positive predictive value better discerned active SLE or flare from inactive disease. The digital ELISA was more sensitive than the bioassay for detecting low-abnormal serum IFNα concentrations and identifying patients with low disease activity.
CONCLUSION: Direct serum IFNα determination with a highly sensitive assay might improve monitoring of clinical SLE activity and selection of the best candidates for anti-IFNα treatment.
© 2018, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30507062     DOI: 10.1002/art.40792

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  16 in total

Review 1.  Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Authors:  Antonios Psarras; Miriam Wittmann; Edward M Vital
Journal:  Nat Rev Rheumatol       Date:  2022-09-12       Impact factor: 32.286

Review 2.  Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment.

Authors:  François Chasset; Jean-Michel Dayer; Carlo Chizzolini
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

3.  Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.

Authors:  A Paradowska-Gorycka; A Wajda; B Stypinska; E Walczuk; E Rzeszotarska; M Walczyk; E Haladyj; K Romanowska-Prochnicka; A Felis-Giemza; A Lewandowska; M Olesińska
Journal:  Clin Exp Immunol       Date:  2021-01-17       Impact factor: 5.732

4.  Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles.

Authors:  John A Reynolds; Tracy A Briggs; Gillian I Rice; Sathya Darmalinggam; Vincent Bondet; Ellen Bruce; Mumtaz Khan; Sahena Haque; Hector Chinoy; Ariane L Herrick; Eoghan M McCarthy; Leo Zeef; Andrew Hayes; Darragh Duffy; Ben Parker; Ian N Bruce
Journal:  Arthritis Res Ther       Date:  2019-06-14       Impact factor: 5.156

5.  Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.

Authors:  Eleftherios Michailidis; Hans-Heinrich Hoffmann; Marwa Chbihi; Stephen J Seligman; Qian Zhang; Margaret R MacDonald; Emmanuelle Jouanguy; Charles M Rice; Jean-Laurent Casanova; Paul Bastard; Tom Le Voyer; Jérémie Rosain; Quentin Philippot; Yoann Seeleuthner; Adrian Gervais; Marie Materna; Patricia Mouta Nunes de Oliveira; Maria de Lourdes S Maia; Ana Paula Dinis Ano Bom; Tamiris Azamor; Deborah Araújo da Conceição; Ekaterini Goudouris; Akira Homma; Günther Slesak; Johannes Schäfer; Bali Pulendran; Joseph D Miller; Ralph Huits; Rui Yang; Lindsey B Rosen; Lucy Bizien; Lazaro Lorenzo; Maya Chrabieh; Lucia V Erazo; Flore Rozenberg; Mohamed Maxime Jeljeli; Vivien Béziat; Steven M Holland; Aurélie Cobat; Luigi D Notarangelo; Helen C Su; Rafi Ahmed; Anne Puel; Shen-Ying Zhang; Laurent Abel
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

Review 6.  Strategies for Immunomonitoring after Vaccination and during Infection.

Authors:  Lucille Adam; Pierre Rosenbaum; Olivia Bonduelle; Behazine Combadière
Journal:  Vaccines (Basel)       Date:  2021-04-09

7.  Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.

Authors:  Nicolas de Prost; Paul Bastard; Romain Arrestier; Slim Fourati; Mathieu Mahévas; Sonia Burrel; Karim Dorgham; Guy Gorochov; Yacine Tandjaoui-Lambiotte; Iname Azzaoui; Ignacio Fernandes; Alain Combes; Jean-Laurent Casanova; Armand Mekontso-Dessap; Charles-Edouard Luyt
Journal:  J Clin Immunol       Date:  2021-02-22       Impact factor: 8.542

8.  Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus.

Authors:  Sylvie Froidevaux; Marianne M Martinic; Daniel S Strasser; Virginie Sippel; Estelle Gerossier; Ursula Grieder; Gabin M Pierlot; Andrea Kieninger-Graefitsch; Enrico Vezzali; Anna K Stalder; Bérengère Renault; Jesper Ryge; Aaron Hart; Ulrich Mentzel; Peter M A Groenen; Marcel P Keller; Marten Trendelenburg; Mark J Murphy
Journal:  RMD Open       Date:  2020-09

9.  Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies.

Authors:  Marit Stockfelt; Gunilla Larsson; Hanna Engström; Henri Puttonen; Henrik Zetterberg; Kaj Blennow; Christopher Sjöwall; Helena Strevens; Andreas Jönsen; Anders A Bengtsson; Maria Majczuk Sennström; Agneta Zickert; Elisabet Svenungsson; Iva Gunnarsson; Estelle Trysberg; Bo Jacobsson; Anna-Karin Hultgård Ekwall; Karin Christenson; Johan Bylund; Mattias N D Svensson; Anna-Carin Lundell
Journal:  Lupus Sci Med       Date:  2021-03

10.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Authors:  Paul Bastard; Lindsey B Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; Quentin Philippot; Jérémie Rosain; Vivien Béziat; Steven M Holland; Guy Gorochov; Emmanuelle Jouanguy; Charles M Rice; Aurélie Cobat; Luigi D Notarangelo; Laurent Abel; Helen C Su; Jean-Laurent Casanova; Jérémy Manry; Elana Shaw; Liis Haljasmägi; Pärt Peterson; Lazaro Lorenzo; Lucy Bizien; Sophie Trouillet-Assant; Kerry Dobbs; Adriana Almeida de Jesus; Alexandre Belot; Anne Kallaste; Emilie Catherinot; Yacine Tandjaoui-Lambiotte; Jeremie Le Pen; Gaspard Kerner; Benedetta Bigio; Yoann Seeleuthner; Rui Yang; Alexandre Bolze; András N Spaan; Ottavia M Delmonte; Michael S Abers; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Lorenzo Piemonti; Fabio Ciceri; Kaya Bilguvar; Richard P Lifton; Marc Vasse; David M Smadja; Mélanie Migaud; Jérome Hadjadj; Benjamin Terrier; Darragh Duffy; Lluis Quintana-Murci; Diederik van de Beek; Lucie Roussel; Donald C Vinh; Stuart G Tangye; Filomeen Haerynck; David Dalmau; Javier Martinez-Picado; Petter Brodin; Michel C Nussenzweig; Stéphanie Boisson-Dupuis; Carlos Rodríguez-Gallego; Guillaume Vogt; Trine H Mogensen; Andrew J Oler; Jingwen Gu; Peter D Burbelo; Jeffrey I Cohen; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio; Paolo Bonfanti; Patrick Rossignol; Julien Mayaux; Frédéric Rieux-Laucat; Eystein S Husebye; Francesca Fusco; Matilde Valeria Ursini; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Xavier Duval; Jade Ghosn; John S Tsang; Raphaela Goldbach-Mansky; Kai Kisand; Michail S Lionakis; Anne Puel; Shen-Ying Zhang
Journal:  Science       Date:  2020-09-24       Impact factor: 63.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.